AVCRF (Avricore Health) Beta: -0.1191 (As of Jun. 27, 2026)


What is Avricore Health Beta?

Avricore Health AVCRF -3.93% Beta is -0.1191 as of Jun. 27, 2026. The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Avricore Health's Beta is -0.1191.


Avricore Health  (OTCPK:AVCRF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Avricore Health Beta Related Terms


Avricore Health Beta Historical Data

* Premium members only.

The historical data trend for Avricore Health's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avricore Health Beta Chart

Avricore Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.46 -1.53 -0.33 0.19 -0.43

Avricore Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.49 0.15 -0.43 0.00

AVCRF vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Avricore Health's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avricore Health Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Avricore Health's Beta distribution charts can be found below:

* The bar in red indicates where Avricore Health's Beta falls into.



Avricore Health Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.1191 mean?
Avricore Health (AVCRF) has a Beta of -0.1191 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Avricore Health and its competitors.
Is Avricore Health's Beta too high?
Avricore Health's current Beta is -0.1191.
How does Avricore Health's Beta compare to TMO and DHR?
Avricore Health's Beta of -0.1191 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Avricore Health and its competitors. Avricore Health's current Beta is -0.1191. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avricore Health stock overvalued right now?
Based on GuruFocus' analysis, Avricore Health (AVCRF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 50.9% above its estimated fair value. The current Beta is -0.1191. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Avricore Health (AVCRF), the current Beta is -0.1191 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avricore Health Business Description

Other Exchanges AVCR:Canada
Address 1120 - 789 West Pender Street, Vancouver, BC, CAN, V6C 1H2
Avricore Health Inc is a Canada-based company. The company is involved in the business of health data and point-of-care technologies. The company has only one segment, being the HealthTab - Point of Care Business in Canada. The company's revenues are generated from operating leases of the POCT system and the sale of testing panels. Geographically, the company operates in Canada and United Kingdom, it derives maximum revenue Canada.